SLC5A2 and hydrops fetalis: However, SGLT2 inhibitors, ARNIs, and MRAs were significantly associated with a decreased risk of hospital admission for HF compared with placebo (SGLT2 inhibitors: HR, 0.71 [95% CrI, 0.60-0.83]; ARNIs: HR, 0.76 [95% CrI, 0.61-0.95]; MRAs: HR, 0.83 [95% CrI, 0.69-0.99]).